Composite Ratios Boost CRP's Power in Monitoring Ulcerative Colitis.

NCT ID: NCT07261579

Last Updated: 2026-01-21

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

80 participants

Study Classification

OBSERVATIONAL

Study Start Date

2025-09-15

Study Completion Date

2025-12-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Inflammatory Bowel Disease (IBD) is a chronic, recurrent condition marked by disturbed levels of various hematological inflammatory cells and a deregulated immune environment. While C-reactive protein (CRP) is a key acute-phase reactant, its high levels can persist even after inflammation subsides. Other simple, cost-effective ratios, such as the Neutrophil-to-Lymphocyte Ratio (NLR), the Platelet-to-Lymphocyte Ratio (PLR), and Albumin-related ratios, also serve as promising, reproducible markers of systemic inflammation reflecting both immune status and nutrition. This study's objective is to evaluate the diagnostic performance of these various hematological inflammatory cellular components and CRP-related ratios (like the CAR) as predictors for Ulcerative Colitis (UC) disease severity, using colonoscopic and microscopic findings as the gold standard for comparison.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Ulcerative Colitis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Ulcerative Colitis Patients

Patients exhibiting clinical signs suggestive of IBD were assessed for UC diagnostic criteria, and the study inclusion and exclusion standards.

C-Reactive Protein measuring CRP

Intervention Type DIAGNOSTIC_TEST

5-ml peripheral blood samples were aseptically obtained for a complete blood count, and ELISA estimation of serum CRP

CRP to Albumin Ratio

Intervention Type DIAGNOSTIC_TEST

Serum CRP to albumin ratio (CAR) is a combination of markers for systemic inflammation and nutritional status

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

C-Reactive Protein measuring CRP

5-ml peripheral blood samples were aseptically obtained for a complete blood count, and ELISA estimation of serum CRP

Intervention Type DIAGNOSTIC_TEST

CRP to Albumin Ratio

Serum CRP to albumin ratio (CAR) is a combination of markers for systemic inflammation and nutritional status

Intervention Type DIAGNOSTIC_TEST

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients who fulfilled the diagnostic criteria for UC;

Exclusion Criteria

* Patients who signed the written consent were enrolled in the study


* Patients who was Previously diagnosed with IBD or IBS;
* Patients with recurrence of manifestations after surgical resection;
* Patients who refused to sign the participation consent.
Minimum Eligible Age

18 Years

Maximum Eligible Age

45 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Benha University

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Raafat R. Mohammed

Assistant consultant of Clinical Pathology

Responsibility Role PRINCIPAL_INVESTIGATOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Alexandria Faculty of medicine

Alexandria, El Alexandria, Egypt

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Egypt

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

E/C. S/N. R14/2025

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.